Pharmacotherapeutic options for atypical meningiomas

References

• Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010 Sep;99(3):307–314.
   PubMed Web of Science ®Google Scholar
• Wang YC, Chuang CC, Wei KC, et al. Long term surgical outcome and prognostic factors of atypical and malignant meningiomas. Sci Rep. 2016 Oct;20(6):35743.
   Google Scholar
• Whittle IR, Smith C, Navoo P, et al. Meningiomas. Lancet. 2004;363(9420):1535–1543.
   PubMed Web of Science ®Google Scholar
• Bagshaw HP, Burt LM, Jensen RL, et al. Adjuvant radiotherapy for atypical meningiomas. J Neurosurg. 2017 Jun;126(6):1822–1828.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug;114(2):97–109.
   PubMed Web of Science ®Google Scholar
• Yang SY, Park CK, Park SH, et al. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008 May;79(5):574–580.
   PubMed Web of Science ®Google Scholar
• Sun SQ, Hawasli AH, Huang J, et al. An evidence-based treatment algorithm for the management of WHO grade II and III meningiomas. Neurosurg Focus. 2015 Mar;38(3):E3.
   PubMed Web of Science ®Google Scholar
• Moazzam AA, Wagle N, Zada G. Recent developments in chemotherapy for meningiomas: a review. Neurosurg Focus. 2013 Dec;35(6):E18.
   PubMed Web of Science ®Google Scholar
• Caruso G, Elbabaa SK, Gonzalez-Lopez P, et al. Innovative therapeutic strategies in the treatment of meningioma. Anticancer Res. 2015;35(12):6391–6400.
   PubMed Web of Science ®Google Scholar
• Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan;122(1):4–23.
   PubMed Web of Science ®Google Scholar
• Paldor I, Awad M, Sufaro YZ, et al. Review of controversies in management of non-benign meningioma. J Clin Neurosci. 2016 Sep;31:37–46.
   PubMed Web of Science ®Google Scholar
• Skeie BS, Enger PO, Skeie GO, et al. Gamma knife surgery of meningiomas involving the cavernous sinus: long-term follow-up of 100 patients. Neurosurgery. 2010 Apr;66(4):661–668; discussion 68–9.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006 Dec;24(8):727–733.
   PubMed Web of Science ®Google Scholar
• Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093–4098.
   PubMed Web of Science ®Google Scholar
• Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993 Jan;15(1):75–77.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007 Sep 4; 69(10):969–973.
   PubMed Web of Science ®Google Scholar
• Schulz C, Mathieu R, Kunz U, et al. Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus. 2011 May;30(5):E11.
   PubMed Web of Science ®Google Scholar
• Norden AD, Ligon KL, Hammond SN, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20;84(3):280–286.
   PubMed Web of Science ®Google Scholar
• Friend KE, Radinsky R, McCutcheon IE. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg. 1999 Jul;91(1):93–99.
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Li JT, Chen L, et al. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res. 2005 Feb 15;65(4):1547–1553.
   PubMed Web of Science ®Google Scholar
• McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg. 2001 Mar;94(3):487–492.
   PubMed Web of Science ®Google Scholar
• Messerer M, Richoz B, Cossu G, et al. Recent advances in the management of atypical meningiomas. Neurochirurgie. 2016 Aug;62(4):213–222.
   PubMed Web of Science ®Google Scholar
• Johnson M, Toms S. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol. 2005 Dec;64(12):1029–1036.
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01–08). Neuro Oncol. 2009 Dec;11(6):853–860.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Dresemann G, Taillibert S, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009;101(12):1995–2004.
   PubMed Web of Science ®Google Scholar
• Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211–217.
   PubMed Web of Science ®Google Scholar
• Lamszus K, Lengler U, Schmidt NO, et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery. 2000 Apr;46(4):938–947; discussion 47–8.
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Alvarez-Argote J, Limonadi FM, et al. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs. Expert Opin Biol Ther. 2018 Dec;17:1–6.
   Google Scholar
• Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug;109(1):63–70.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014 Mar;117(1):93–101.
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan;17(1):116–121.
   PubMed Web of Science ®Google Scholar
• Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997 May;86(5):845–852.
   PubMed Web of Science ®Google Scholar
• Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997 May;86(5):840–844.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012 Apr;107(2):315–321.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Barnholtz-Sloan JS. Medical treatment of recurrent meningiomas. Expert Rev Neurother. 2011 Oct;11(10):1425–1432.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol. 2011 Sep;104(3):765–771.
   PubMed Web of Science ®Google Scholar
• Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002 Aug;97(2):341–346.
   PubMed Web of Science ®Google Scholar
• Sherman WJ, Raizer JJ. Chemotherapy: what is its role in meningioma? Expert Rev Neurother. 2012 Oct;12(10):1189–1195; quiz 96.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004 Apr 13;62(7):1210–1212.
   PubMed Web of Science ®Google Scholar
• Gupta V, Su YS, Samuelson CG, et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007 Mar;106(3):455–462.
   PubMed Web of Science ®Google Scholar
• Huisman TW, Tanghe HL, Koper JW, et al. Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics. Eur J Cancer. 1991;27(11):1453–1457.
   PubMed Web of Science ®Google Scholar
• Preusser M, Spiegl-Kreinecker S, Lotsch D, et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer. 2012 Oct 15;118(20):5038–5049.
   PubMed Web of Science ®Google Scholar
• Curic S, Wu Y, Shan B, et al. Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas. J Neurooncol. 2013 Jul;113(3):385–396.
   PubMed Web of Science ®Google Scholar
• Park YS, Lee JH, Harwalkar JA, et al. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. Adv Exp Med Biol. 2002;507:387–393.
   PubMed Web of Science ®Google Scholar
• Glaser T, Winter S, Groscurth P, et al. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer. 1999 May 1;80(5):756–765.
   PubMed Web of Science ®Google Scholar
• Roy NK, Deka A, Bordoloi D, et al. The potential role of boswellic acids in cancer prevention and treatment. Cancer Lett. 2016 Jul 10;377(1):74–86.
   PubMed Web of Science ®Google Scholar
• Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997 Feb;40(2):271–275.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008 Oct 15;113(8):2146–2151.
   PubMed Web of Science ®Google Scholar
• Barresi V, Lionti S, La Rocca L, et al. High p-mTOR expression is associated with recurrence and shorter disease-free survival in atypical meningiomas. Neuropathology. 2019 Feb;39(1):22–29.
   PubMed Web of Science ®Google Scholar
• Klinger DR, Flores BC, Lewis JJ, et al. Atypical meningiomas: recurrence, reoperation, and radiotherapy. World Neurosurg. 2015 Sep;84(3):839–845.
   PubMed Web of Science ®Google Scholar
• Sayagués JM, Tabernero MD, Maíllo A, et al. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH). J Mol Diagn. 2004;6(4):316–325.
   PubMed Web of Science ®Google Scholar
• Harmanci AS, Youngblood MW, Clark VE, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2017 Feb 14;8:14433.
   PubMed Web of Science ®Google Scholar
• El-Gewely MR, Andreassen M, Walquist M, et al. Differentially expressed microRNAs in meningiomas grades I and II suggest shared biomarkers with malignant tumors. Cancers (Basel). 2016 Mar 3;8(3):31.
   PubMed Web of Science ®Google Scholar
• Zador Z, King AT, Geifman N. New drug candidates for treatment of atypical meningiomas: an integrated approach using gene expression signatures for drug repurposing. PLoS One. 2018;13(3):e0194701.
   PubMed Web of Science ®Google Scholar